Analysts Set Teleflex Incorporated (NYSE:TFX) Target Price at $252.50

Shares of Teleflex Incorporated (NYSE:TFX) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $252.50.

TFX has been the topic of a number of recent analyst reports. Mizuho cut their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada reduced their price objective on Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Truist Financial reduced their price target on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Finally, StockNews.com upgraded shares of Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th.

Teleflex Stock Down 0.3 %

TFX stock opened at $179.51 on Wednesday. The business has a 50 day moving average of $196.65 and a 200 day moving average of $218.19. The firm has a market cap of $8.34 billion, a PE ratio of 35.69, a price-to-earnings-growth ratio of 1.84 and a beta of 1.16. Teleflex has a twelve month low of $171.69 and a twelve month high of $256.85. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, beating the consensus estimate of $3.38 by $0.11. The firm had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $3.64 earnings per share. On average, research analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date was Friday, November 15th. Teleflex’s dividend payout ratio (DPR) is 27.04%.

Institutional Investors Weigh In On Teleflex

A number of institutional investors have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund grew its position in shares of Teleflex by 1.2% during the second quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock worth $846,000 after purchasing an additional 46 shares in the last quarter. Cromwell Holdings LLC grew its holdings in Teleflex by 59.0% during the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after buying an additional 49 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Teleflex by 1.9% during the second quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock valued at $584,000 after buying an additional 53 shares during the last quarter. Apollon Wealth Management LLC lifted its holdings in shares of Teleflex by 3.7% in the third quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock worth $377,000 after buying an additional 55 shares in the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in shares of Teleflex by 0.3% during the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company’s stock worth $4,844,000 after acquiring an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.